These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31992459)

  • 1. Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State.
    Jang K; Jeon JY; Moon SJ; Kim MG
    Clin Ther; 2020 Feb; 42(2):295-304. PubMed ID: 31992459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
    Kim YK; Hwang JG; Park MK
    Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.
    Moon SJ; Yu KS; Kim MG
    Clin Ther; 2020 Jun; 42(6):1047-1057. PubMed ID: 32362346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects.
    Kim CO; Sil Oh E; Kim C; Park MS
    Clin Ther; 2015 Sep; 37(9):1999-2006.e1. PubMed ID: 26163202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
    Tang W; Engman H; Zhu Y; Dayton B; Boulton DW
    Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
    Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects.
    Kim SY; Jeon JY; Park SJ; Kim MG
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):576-584. PubMed ID: 30329224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.
    Sil Oh E; Ok Kim C; Kim KH; Kim YN; Kim C; Lee JI; Park MS
    Clin Ther; 2014 Jul; 36(7):1064-71. PubMed ID: 25047497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
    Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.
    Vakkalagadda B; Lubin S; Reynolds L; Liang D; Marion AS; LaCreta F; Boulton DW
    Clin Ther; 2016 Aug; 38(8):1890-9. PubMed ID: 27491280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
    Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects.
    Khomitskaya Y; Tikhonova N; Gudkov K; Erofeeva S; Holmes V; Dayton B; Davies N; Boulton DW; Tang W
    Clin Ther; 2018 Apr; 40(4):550-561.e3. PubMed ID: 29548719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
    Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
    Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioequivalence of 0.5 mg lobeglitazone tablets in healthy male subjects
.
    Lee SJ; Kim MG; Park SJ; Jeon JY
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):426-433. PubMed ID: 29932413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.
    Park MK; Kim TE; Kim J; Kim C; Yoon SH; Cho JY; Jang IJ; Yu KS; Lim KS
    Clin Drug Investig; 2014 Jul; 34(7):467-74. PubMed ID: 24802657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
    Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
    Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
    Kim JW; Kim JR; Yi S; Shin KH; Shin HS; Yoon SH; Cho JY; Kim DH; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2011 Nov; 33(11):1819-30. PubMed ID: 22047812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
    Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
    Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.